KORU Medical Q3 revenue $10.4M (+27% YoY), raises full-year guidance

KORU Medical Systems, Inc.

2025-Q3 EPS reported $0.05 revenue$30,232,038

Q3 net revenues $10.4M, up 27% YoY; core business (domestic + international) $9.8M, up 30%.
Net loss narrowed 51% to $0.8M; positive adjusted EBITDA of $0.09M vs. $(0.4M) prior year.
International core revenue surged 229.6% to $3.7M; domestic core declined 5.0%.
Raising FY2025 revenue guidance to $40.5-41.0M (from $39.5-40.5M); gross margin guidance reiterated at 61-63%.
Ending cash balance $8.5M; generated $0.4M cash in Q3; reiterating positive full-year cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.